Description
OVERVIEWProduct overview
This is the modified GRF (1-29) sequence supplied without the drug affinity complex, giving a much shorter profile than the DAC version.
It is generally selected where a research question concerns pulsatile rather than sustained receptor signalling.
Laboratory research use only.
SUPPLY IN IRELANDCJC-1295 without DAC Ireland — supplied to research laboratories
Research groups across Ireland buy CJC-1295 without DAC from Kensington Laboratories as a lyophilised CJC-1295 without DAC peptide, released only against a batch-matched certificate of analysis. Every vial of high purity CJC-1295 without DAC is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering CJC-1295 without DAC in Ireland receive material with documented purity and identity.
Laboratory CJC-1295 without DAC is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning CJC1295withoutDAC research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for CJC-1295 without DAC peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
CJC-1295 without DAC is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 5 mg or 10 mg per vial
- Peptide class: Growth hormone releasing hormone analogue (1-29) without affinity complex
- Also known as: Modified GRF (1-29), Mod GRF 1-29, sermorelin analogue
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
This is the modified GRF (1-29) sequence supplied without the drug affinity complex, giving a much shorter profile than the DAC version.
It is generally selected where a research question concerns pulsatile rather than sustained receptor signalling.
Laboratory research use only.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- GHRH receptor pathway studies
- Pulsatile signalling models
- Short-profile versus DAC comparison arms
- Peptide stability and handling research
Scientific context and proposed mechanisms
The peptide engages the GHRH receptor on pituitary somatotrophs. Four amino acid substitutions relative to native GHRH are described as improving resistance to enzymatic degradation.
Without the affinity complex, clearance is rapid, which is the property that makes it useful in pulsatility comparisons.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-CJC1295WIT-2406A
- Testing laboratory
- Colmaric Analyticals
- Date tested
- 9 June 2026
- Reported purity
- 99.31%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS





